{"organizations": ["Immune Pharmaceuticals"], "uuid": "3c0a4ec60c883bb16f67275bf585f177acdd08e4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530610?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Immune Pharmaceuticals sells $9.5mm in preferred shares to Discover Growth Fund; additional $3mm possible", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Immune Pharmaceuticals sells $9.5mm in preferred shares to Discover Growth Fund; additional $3mm possible", "spam_score": 0.0, "site_type": "news", "published": "2015-08-06T02:40:00.000+03:00", "replies_count": 0, "uuid": "3c0a4ec60c883bb16f67275bf585f177acdd08e4"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530610?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Immune Pharmaceuticals sells $9.5mm in preferred shares to Discover Growth Fund; additional $3mm possible", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Immune Pharmaceuticals sells $9.5mm in preferred shares to Discover Growth Fund; additional $3mm possible Deal Date: Jul-01-2015 / Deal # 201530610 Executive Summary \nImmune Pharmaceuticals Inc. (pain, inflammation, dermatology, and cancer therapies) sold to the mutual fund Discover Growth Fund 947 Series D preferred shares (444 issued through a registered direct offering and 503 in a private placement) at $10k apiece for gross proceeds of $9.5mm. At the end of the six-and-a-half-year maturity term, the shares automatically convert to common at $2.50. (Immune's stock was averaging $1.82 at the time of the sale.) The company could receive an additional $3mm in proceeds from a resale registration of another 316 Series D preferred shares (effective upon stockholder approval). Roth Capital Partners and Chardan Capital Markets were the placement agents.", "external_links": [], "published": "2015-08-06T02:40:00.000+03:00", "crawled": "2015-08-06T14:43:56.925+03:00", "highlightTitle": ""}